Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects-Reference-Cited by-同舟云学术

Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects

Published:2017-12-28 Issue:5 Volume:38 Page:1447-1468
ISSN:0198-6325
Container-title:Medicinal Research Reviews
language:en
Short-container-title:Med. Res. Rev.

Author:

Spallarossa Paolo¹,Meliota Giovanni¹,Brunelli Claudio¹,Arboscello Eleonora²,Ameri Pietro¹,Dessalvi Christian Cadeddu³,Grossi Francesco⁴,Deidda Martino³,Mele Donato⁵,Sarocchi Matteo¹,Bellodi Andrea²,Madonna Rosalinda⁶⁷^ORCID,Mercuro Giuseppe³

Affiliation:

1. Clinic of Cardiovascular Disease, Policlinic Hospital; IRCCS San Martino IST; Genova Italy

2. Clinic of Internal Medicine, Policlinic Hospital; IRCCS San Martino IST; Genova Italy

3. Mario Aresu Department of Medical Sciences; University of Cagliari; Cagliari Italy

4. Medical Oncology, Policlinic Hospital; IRCCS San Martino IST; Genova Italy

5. Cardiology Unit; Emergency Department; University Hospital of Ferrara; Ferrara Italy

6. Center of Aging Sciences and Translational Medicine-CESI-MeT and Department of Neurosciences, Imaging, and Clinical Sciences, Institute of Cardiology; “G. d'Annunzio” University; Chieti Italy

7. Department of Internal Medicine; Texas Heart Institute and University of Texas Medical School in Houston; Houston TX USA

Publisher

Wiley

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/med.21478/fullpdf

Reference69 articles.

1. Cancer immunotherapy comes of age;Mellman;Nature,2011

2. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

3. Evolving concepts: immunity in oncology from targets to treatments;Khan;J Oncol,2015

4. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system;Pico de Coaña;Trends Mol Med,2015

5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myocardial extracellular volume derived from contrast-enhanced chest computed tomography in longitudinal evaluation of cardiac toxicity in patients treated with immune checkpoint inhibitors;Quantitative Imaging in Medicine and Surgery;2024-04

2. The diverse effects of cisplatin on tumor microenvironment: Insights and challenges for the delivery of cisplatin by nanoparticles;Environmental Research;2024-01

3. Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity;Advances in Clinical Medicine;2024

4. Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go;Angiology;2023-09-12

5. Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs;Antioxidants;2023-07-03